Double-blind 200 mg imsidolimab
ANB019-302
Phase 3 small_molecule terminated
Quick answer
Double-blind 200 mg imsidolimab for Generalized Pustular Psoriasis is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vanda Pharmaceuticals
- Indication
- Generalized Pustular Psoriasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated